総合バリュエーションレンジ · 保守的 HK$31–HK$34 / 妥当 HK$47–HK$64 / 楽観的 HK$87–HK$95。HK$46.7 時点で 保守的レンジと妥当レンジの間。
レポート公開時 HK$48.3（2026年6月17日）
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
データ提供：EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
沿革
近日公開このセクションは現在準備中です。近日公開予定です。
業界での地位
近日公開このセクションは現在準備中です。近日公開予定です。